Long-term outcome of quetiapine use for psychosis among Parkinsonian patients

Mov Disord. 2003 May;18(5):510-4. doi: 10.1002/mds.10374.


To evaluate the long-term efficacy and tolerability of quetiapine for psychosis among parkinsonian patients, a retrospective analysis of all parkinsonian patients taking quetiapine for psychosis in a single movement disorders center was carried out. Demographic data, including type and severity of psychosis, presence of dementia, treatment response, before and after Unified Parkinson's Disease Rating Scale (UPDRS)-motor scores and Hoehn and Yahr (H&Y) scale were obtained. One hundred six parkinsonian patients with a mean age of 76.6 years were on an average levodopa (L-dopa) dose of 415 mg/d. Seventy-eight of 106 (74%) remained on quetiapine for a mean duration of 15 months at an average dose of 60 mg per day. Eighty-seven (82%) patients had partial or complete resolution of their psychosis whereas 19 (18%) patients had no improvement on quetiapine. Motor worsening was noted in 34 (32%) patients but was uncommonly sufficient to warrant quetiapine discontinuation. More quetiapine non-responders were noted to be demented, delusional, and experienced threatening psychosis but only the presence of dementia remained significant on multivariate analysis (OR = 11.6; 95% CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07).

Publication types

  • Evaluation Study

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Dibenzothiazepines / adverse effects
  • Dibenzothiazepines / therapeutic use*
  • Drug Tolerance
  • Dyskinesia, Drug-Induced / diagnosis
  • Dyskinesia, Drug-Induced / epidemiology
  • Dyskinesia, Drug-Induced / etiology
  • Female
  • Follow-Up Studies
  • Humans
  • Levodopa / therapeutic use
  • Male
  • Outcome Assessment, Health Care
  • Parkinson Disease / drug therapy
  • Parkinson Disease / psychology*
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / epidemiology
  • Psychotic Disorders / etiology*
  • Quetiapine Fumarate
  • Retrospective Studies
  • Severity of Illness Index


  • Antiparkinson Agents
  • Antipsychotic Agents
  • Dibenzothiazepines
  • Quetiapine Fumarate
  • Levodopa